More and more imaging researchers are starting to examine the potential of using fibroblast activation protein inhibitors (FAPI) to manage patients with suspected cardiovascular disease.
The BENEFIT-HF trial, scheduled to begin enrollment in the months ahead, could significantly increase the number of patients eligible for CVRx's Barostim therapy.
Shockwave Medical, now a part of Johnson & Johnson MedTech, sits at the top of the IVL market, but things are starting to get more competitive. Boston Scientific gained its own IVL system when it acquired Bolt Medical in 2025.
Gene-editing drugs have shown potential to treat a wide variety of diseases, and this will be one of the first in cardiovascular medicine to begin human trials.
Results demonstrate how implementing adjusted procedures to limit radiation exposures for children may lower cancer risks and save on health care costs.
“Before we examined the data, I thought we would find an ample amount of the symptoms to be specifically associated with long COVID, but that wasn’t the case," one researcher said.
The model augmented and significantly improved diagnostic performance for abdominal subspecialists as well as residents—a result researchers say has major clinical implications.
